ClinicalTrials.gg
CompletedNCT02536209Updated Dec 22, 2025

A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects

A Phase 1 interventional study of MT-8554 low dose and MT-8554 high dose in Healthy, sponsored by Tanabe Pharma Corporation. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Tanabe Pharma Corporation · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the pharmacodynamic effect of single doses of MT-8554 in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy and free from illness or disease
  • Male Caucasian subjects aged 18 to 55
  • A body weight of ≥60 kg

Exclusion criteria

Exclusion Criteria:

  • Participation in more than three clinical studies involving administration of an Medicinal Product (IMP) in the previous year, or any study within 12 weeks.
  • endocrine, thyroid, hepatic, respiratory, gastro-intestinal, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder.
  • Clinically relevant abnormal medical history, physical findings or laboratory values
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Regimen 1

    Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing

    Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo

  • Experimental
    Regimen 2

    Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing

    Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo

  • Experimental
    Regimen 3

    Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing

    Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo

  • Experimental
    Regimen 4

    Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing

    Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Pharmacodynamic effect as measured by Visual Analogue Scale for Cold Pressor Test

    Time frame: up to 10 hours post dosing

Secondary outcomes

  1. Safety and Tolerability as measured by vital signs

    Time frame: up to Day6 of treatment period 4

  2. Safety and Tolerability as measured by ECG

    Time frame: up to Day6 of treatment period 4

  3. Safety and Tolerability as measured by laboratory safety assessments

    Time frame: up to Day6 of treatment period 4

  4. Safety and Tolerability as measured by physical examination

    Time frame: up to Day6 of treatment period 4

  5. Safety and Tolerability as measured by number of participants with adverse events

    Time frame: up to Day6 of treatment period 4

  6. Plasma concentration of MT-8554 at the time of Pharmacodynamic assessments

    Time frame: up to 10 hours post dosing

  7. Plasma concentration of Oxycodone hydrochloride at the time of Pharmacodynamic assessments

    Time frame: up to 10 hours post dosing

07

Study locations

1 site
  • Investigational center
    City Name, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2015
First posted
Aug 31, 2015
Start
Aug 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02536209
Responsible party
Sponsor
First posted
Aug 31, 2015
Start date
Aug 2015
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Dec 22, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion